You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The deal includes UK-based Yourgene's test for detecting cancer patients who may have an adverse reaction to 5-fluorouracil, as well as reproductive health tests.
The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.
The organization had previously only recommended the use of noninvasive prenatal testing in individuals 35 and older or with other known risk factors.
Revenue growth in Q2 was driven by strong sales of the company's Panorama noninvasive prenatal test and Horizon carrier screening test.
As reported in April, revenues for the fiscal year ended March 31 totaled £16.6 million ($21.4 million), up from £8.9 million in FY2019.
First Genetics will market its F-Genetics NGS System and IVD assays to Russian laboratories for reproductive health testing and cancer diagnostics.
Natera sued Progenity in June but the firm said its Innatal cell-free DNA noninvasive prenatal test does not infringe any of Natera's six patents.
The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.
Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.
Revenues for the fiscal year totaled £16.6 million ($20.7 million), up from £8.9 million during FY 2019.